Risk Factors in Cardiovascular Disease in Systemic Lupus Erythematosus

Sinicato, Nailú Angélica; Cardoso, Priscila Aparecida da Silva; Appenzeller, Simone

doi:10.2174/1573403x11309010003

Cited by 9 publications

(9 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The existence of hypertension and use of anti-hypertensive drugs might counteract the each effect. Corticosteroid is considered as a possible risk factor for cardiovascular disease in patients with systemic lupus erythematosus [20]. Korkmaz et al also implied that the prevalence of steroid therapy is higher among patients with systemic lupus erythematosus accompanied with, than without coronary atherosclerosis [21].…”

Section: Discussionmentioning

confidence: 99%

Long-Term Survival of Patients with IgA Nephropathy After Dialysis Therapy

Komatsu

Kikuchi

Nakagawa

et al. 2013

Kidney Blood Press Res

View full text Add to dashboard Cite

Background/Aims: How dialysis affects the survival of patients with biopsy-proven IgA nephropathy (IgAN) is not fully understood. The present long-term cohort study quantifies the survival rates and incidence of cardio-cerebrovascular diseases (CCVDs) among such patients in Japan. Methods: Fifty-two of 433 patients with IgAN who had reached end-stage kidney disease underwent renal replacement therapy (RRT) between 1981 and 2010. The overall survival rate and incidence of CCVDs in these patients were evaluated during follow-up for 11.3 ± 6.4 years. Results: The mean age at starting RRT was 42.8 ± 13.3 years. Only seven patients died during follow-up (mortality rate, 1.2/100 person-years) and Kaplan-Meier analysis revealed favorable survival rates of 93.3% and 65.1% at 10 and 20 years, respectively, compared with that of patients with glomerulonephritis in the registry of the Japanese Society for Dialysis Therapy who required RRT. Malignancy and CCVDs were causes of death at 13.6 ± 4.8 and 3.9 ± 1.3 years, respectively, after starting RRT. Fatal and non-fatal CCVDs developed in 15 (incidence, 2.7/100 person-years) patients and acute coronary syndrome and cerebral hemorrhage developed relatively soon after starting RRT. Cox proportional hazards models revealed that age at the time of starting RRT was a significant factor affecting the onset of CCVDs. Meanwhile, a history of having had corticosteroid as an initial treatment did not affect the onset of events. Conclusion: Although the survival of patients with IgAN is favorable after dialysis, the onset of CCVDs during the early phase of dialysis should be carefully monitored.

show abstract

Section: Discussionmentioning

confidence: 99%

Long-Term Survival of Patients with IgA Nephropathy After Dialysis Therapy

Komatsu

Kikuchi

Nakagawa

et al. 2013

Kidney Blood Press Res

View full text Add to dashboard Cite

show abstract

“…Conventional CV risk factors such as diabetes mellitus (DM), hypertension (HT) and dyslipidaemia were reported to be increased in patients with LN as compared with patients with SLE without nephritis. [14][15][16][17] Other contributing factors for atherosclerotic CVD in patients with LN include presence of renal impairment and proteinuria. 17 18 Indeed, renal insufficiency and proteinuria are both well-recognised risk factors for atherosclerotic CVD, and CVD in fact is the leading cause of mortality in patients with renal failure.…”

Section: Lupus Science and Medicinementioning

confidence: 99%

Cardiovascular risk factors and complications in patients with systemic lupus erythematosus with and without nephritis: a systematic review and meta-analysis

Wong,

Ma,

Zhang

et al. 2024

Lupus Sci Med

View full text Add to dashboard Cite

IntroductionIt remains unclear how the presence of renal involvement will affect the cardiovascular (CV) risk factors and complications in patients with SLE.MethodsWe conducted a systematic review and meta-analysis using PubMed, EMBASE, MEDLINE and Scopus to identify studies published between 1947 and 2022 that evaluate the CV risk factors and complications in patients with SLE with or without lupus nephritis (LN).Results58 studies were evaluated, with 22 two-arm studies (n=8675) included in two-arm meta-analysis and 45 studies (n=385 315) included in proportional meta-analysis. Patients with SLE with LN showed significantly higher risk of hypertension (HT) (OR=4.93, 95% CI=3.17 to 7.65, p<0.00001, I2=56%), hyperlipidaemia (OR=11.03, 95% CI=4.20 to 28.95, p<0.00001, I2=0%) and diabetes mellitus (DM) (OR=1.88, 95% CI=1.09 to 3.25, p=0.02, I2=32%) compared with those without LN. Patients with LN showed numerically higher prevalence of myocardial infarction (OR=1.35, 95% CI=0.53 to 3.45, p=0.52, I2=78%) and cerebrovascular accident (OR=1.64, 95% CI=0.79 to 3.39, p=0.27, I2=23%) than general patients with SLE. The incidence rates of CV mortality are also increased in patients with SLE with LN compared with those without LN (11.7/1000 patient-years vs 3.6/1000 patient-years).ConclusionPatients with SLE with LN show increased risk of CV risk factors including DM, HT and hyperlipidaemia. Early identification and optimal control of these CV risk factors may reduce the risk of CV disease and other non-CV complications.PROSPERO registration numberCRD42022314682.

show abstract

“…pSS predominately affects females (9 : 1), with a frequency in the overall population from 0.1 to 0.6%. Studies evaluating patients with rheumatoid arthritis (RA) [2] and systemic lupus erythematosus (SLE) [103] have shown that inflammation plays a role in the progression of hypertension, diabetes mellitus, and MetS [104]. …”

Section: Id3 and Disease Outcomesmentioning

confidence: 99%

Contribution of Inhibitor of DNA Binding/Differentiation-3 and Endocrine Disrupting Chemicals to Pathophysiological Aspects of Chronic Disease

Avecilla

Doke

Felty

2017

BioMed Research International

View full text Add to dashboard Cite

The overwhelming increase in the global incidence of obesity and its associated complications such as insulin resistance, atherosclerosis, pulmonary disease, and degenerative disorders including dementia constitutes a serious public health problem. The Inhibitor of DNA Binding/Differentiation-3 (ID3), a member of the ID family of transcriptional regulators, has been shown to play a role in adipogenesis and therefore ID3 may influence obesity and metabolic health in response to environmental factors. This review will highlight the current understanding of how ID3 may contribute to complex chronic diseases via metabolic perturbations. Based on the increasing number of reports that suggest chronic exposure to and accumulation of endocrine disrupting chemicals (EDCs) within the human body are associated with metabolic disorders, we will also consider the impact of these chemicals on ID3. Improved understanding of the ID3 pathways by which exposure to EDCs can potentiate complex chronic diseases in populations with metabolic disorders (obesity, metabolic syndrome, and glucose intolerance) will likely provide useful knowledge in the prevention and control of complex chronic diseases associated with exposure to environmental pollutants.

show abstract

Risk Factors in Cardiovascular Disease in Systemic Lupus Erythematosus

Cited by 9 publications

References 38 publications

Long-Term Survival of Patients with IgA Nephropathy After Dialysis Therapy

Long-Term Survival of Patients with IgA Nephropathy After Dialysis Therapy

Cardiovascular risk factors and complications in patients with systemic lupus erythematosus with and without nephritis: a systematic review and meta-analysis

Contribution of Inhibitor of DNA Binding/Differentiation-3 and Endocrine Disrupting Chemicals to Pathophysiological Aspects of Chronic Disease

Contact Info

Product

Resources

About